Roche chairman still expects diagnostics hit from US tariffs - Reuters

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOcTRSeDZTWGVUbnNiMkEzR3E3RGExeWtEandjbG1YX0Rod1BkN2xkeTVKSktOandObWxkOVpFazBpb0dnNjBQdEx4WlVqUTluS3JYcUNfV1JLNXM3TE1adzJGbENxa19Ld1VCajRvWUZ3V1ZwUjdkWlBEUlZJaC0wMXZPcWNLd0dfRUdMSmlYTmF2c2NYMDlaWllPU0JhcDdDS1lNU3lnRjNJbmhqMVkyRGRYam1HLTNld3FTbGZaZ2pPU3dWeXc?oc=5" target="_blank">Roche chairman still expects diagnostics hit from US tariffs</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Roche's Chairman Severin Schwan anticipates that while the company's pharmaceutical imports will remain exempt from U.S. tariffs due to an existing agreement, its diagnostics division may face renewed duties after an initial 150-day period.

Despite an agreement with the U.S. government, Roche's diagnostics division remains exposed to potential tariffs after an initial 150-day period, according to Chairman Severin Schwan.

Roche's Chairman Severin Schwan indicates that while the pharmaceutical division is exempt from U.S. tariffs, the diagnostics division could face renewed duties after an initial 150-day period.

Roche's Chairman Severin Schwan anticipates that the diagnostics division may face renewed U.S. import tariffs after an initial 150-day period, despite an agreement exempting pharmaceuticals.

Roche's Chairman Severin Schwan indicates that while the pharmaceutical division is exempt from U.S. tariffs, the diagnostics division could face renewed duties after an initial 150-day period.

Roche's Chairman Severin Schwan anticipates that while the company's pharmaceutical imports will remain exempt from current US tariffs, its diagnostics division may face renewed duties after an initial 150-day period.